ZPW  
1636

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

|  |                      |                        |         |
|--|----------------------|------------------------|---------|
|  | Application Number   | 09/990,522             |         |
|  | Filing Date          | November 21, 2001      |         |
|  | First Named Inventor | Choy-Pik Chiu, et al.  |         |
|  | Art Unit             | 1636                   |         |
|  | Examiner Name        | Thaian N. Ton          |         |
| Total Number of Pages in This Submission | 4                    | Attorney Docket Number | 097/002 |

**ENCLOSURES (Check all that apply)**

|  |  |   |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached   | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers   | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): |
| <input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)               | <input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br><input type="checkbox"/> Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD |   |
| <input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request   | Remarks  |   |
| <input checked="" type="checkbox"/> Information Disclosure Statement Following Request for Continued Examination (2 pages)                           | PTO Form 1449 (1 page) with copies of 10 references  |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)  |  |   |
| <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 |  |   |

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

|              |                   |          |        |
|--------------|-------------------|----------|--------|
| Firm Name    | Geron Corporation |          |        |
| Signature    |                   |          |        |
| Printed name | J. Michael Schiff |          |        |
| Date         | April 12/05       | Reg. No. | 40,253 |


**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

|                       |              |      |                |
|-----------------------|--------------|------|----------------|
| Signature             |              |      |                |
| Typed or printed name | Geron Zielan | Date | April 12, 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

CERTIFICATE OF FIRST CLASS MAIL

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated:

Karen Ziemer  
*Name*

April 12, 2005  
*Date*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Choy-Pik Chiu, *et al.*

Art Unit: 1636

Serial No.: 09/990,522

Examiner: Quang Nguyen

Filing Date: November 21, 2001

Docket: 097/002

For: TOLERIZING ALLOGRAFTS OF PLURIPOTENT  
STEM CELLS

INFORMATION DISCLOSURE STATEMENT

PURSUANT TO 37 CFR § 1.97(b)(4)

FOLLOWING REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents  
Alexandria, VA 22313-1450


Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

This Disclosure is being filed shortly after a Request for Continued Examination under 37 CFR § 1.114, and before a subsequent Action on the merits of the application. Accordingly, this IDS complies with the provisions of 37 CFR § 1.97(b)(4), and no fee is believed payable. Nevertheless, should the Office determine that a fee is required for further consideration of the application, the Commissioner is hereby authorized to charge said fees (or credit any overpayment) to Deposit Account 07-1139.

Respectfully submitted,



J. Michael Schiff  
Registration No. 40,253

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
Telephone: (650) 473-7715  
Fax: (650) 473-8654

April 12, 2005

|   |  |                      |
|---|--|----------------------|
| Form 1449 (modified)  | Docket: 097/002  | U.S.S.N.: 09/990,522 |
| <b>Supplemental Information Disclosure Statement By Applicant</b><br><i>OTPE</i><br>(Use Several Sheets if Necessary) | Title: Tolerizing Allografts of Pluripotent Stem Cells<br>Inventors: Choy-Pik Chiu, et al. |                      |
|   | Filing Date: November 21, 2001   | Group: 1636          |

APR 15 2005

**U.S. Patent Documents**

| Examiner Initial | Ref. | Document No. | Filing Date | Publication Date | Class/Subclass | Inventors | Title |
|------------------|------|--------------|-------------|------------------|----------------|-----------|-------|
| none             |      |              |             |                  |                |           |       |

**Foreign Patent or Published Foreign Patent Application**

| Examiner Initial | Ref. | Document No. | Publication Date | Jurisdiction | Title   | Translation |
|------------------|------|--------------|------------------|--------------|---|-------------|
|                  | GA   | WO 01/51616  | July 19/01       | PCT          | Techniques for Growth and Differentiation of Human Pluripotent Stem Cells | N/A         |

**Other Documents**

| Examiner Initial | Ref. | Author, Title, Source, Date   |
|------------------|------|---|
|                  | GB   | Abraham EJ et al, Human Pancreatic Islet-Derived Progenitor Cell Engraftment in Immunocompetent Mice, Am J Pathology 164(3):817 (2004)  |
|                  | GC   | Aggarwal S et al, Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses, Blood 105(4):1815 (2005)  |
|                  | GD   | Colson YL et al, Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts, J Immunology 173:5827 (2004)   |
|                  | GE   | Harley CB, Telomerase is Not an Oncogene, Oncogene 21:494 (2002)  |
|                  | GF   | Moustafa ME et al, Chimerism and Tolerance Post-In Utero Transplantation with Embryonic Stem Cells, Transpl 78(9):1274 (2004)   |
|                  | GG   | Sasaki K et al, Hematopoietic Microchimerism in Sheep After In Utero Transplantation of Cultured Cynomolgus Embryonic Stem Cells, Transpl 79(1):32 (2005)   |
|                  | GH   | Xu C et al, Immortalized Fibroblast-Like Cells Derived from Human Embryonic Stem Cells Support Undifferentiated Cell Growth, Stem Cells 22:972 (2004), and supplemental information available over the internet from the journal as part of the publication |
|                  | GI   | Xu C et al, Osteoblast Precursors from Human Embryonic Stem Cells, U.S. Provisional Patent Application S/N 60/303,732, July 6, 2001   |
|                  | GJ   | Xu C, Cells of the Cardiomyocyte Lineage Produced from Human Pluripotent Stem Cells, U.S. Provisional Patent Application S/N 60/322,695, Sept 10/01   |

| Examiner | Date Considered |
|----------|-----------------|
|          |                 |

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**  
 PTO-1449 — Page 1